Releasing Dynamic of Serum ST2 and Calprotectin in Patients with Acute Ischemic Stroke.
Ana SrukHrvoje BudincevicAna-Maria SimundicLora DukićTena Sučić RadovanovićHelena ČičakDaria PašalićPublished in: Diagnostics (Basel, Switzerland) (2024)
This study investigated the releasing dynamics of serum ST2 and calprotectin in patients with acute IS. The study included acute IS patients (N = 20) with an NIH Stroke Scale score ≥8. Sampling was performed at seven time points: after admission (T0) and at the following 24 h consecutive intervals (T1-T6). Primary outcome at 90 days was evaluated using the modified Rankin scale: 0-2 for good and 3-6 for poor functional outcome. The secondary outcome was all-cause mortality after 90 days. Fifteen patients had a poor outcome, and eight died. Results showed a statistically significant difference in ST2 concentrations between good and poor outcomes at T0 ( p = 0.04), T1 ( p = 0.006), T2 ( p = 0.01), T3 ( p = 0.021), T4 ( p = 0.007), T5 ( p = 0.032), and for calprotectin T6 ( p = 0.034). Prognostic accuracy was highest for ST2 at T1 for a cut-off > 18.9 µg/L (sensitivity 80% and specificity 100.0%) and for calprotectin at T5 for a cut-off > 4.5 mg/L (sensitivity 64.3% and specificity 100.0%). Serum ST2 and calprotectin-releasing dynamics showed a valuable prognostic accuracy for IS outcomes.
Keyphrases
- end stage renal disease
- acute ischemic stroke
- newly diagnosed
- ejection fraction
- chronic kidney disease
- disease activity
- emergency department
- atrial fibrillation
- metabolic syndrome
- liver failure
- systemic lupus erythematosus
- intensive care unit
- patient reported outcomes
- skeletal muscle
- type diabetes
- hepatitis b virus